Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
About this item
Full title
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
The New England journal of medicine, 2017-08, Vol.377 (8), p.723-732
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized, double-blind trial involving patients with type 2 diabetes at high risk for cardiovascular events, basal insulin degludec was noninferior to glargine with respect to major cardiovascular events.
Alternative Titles
Full title
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5731244
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5731244
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1615692
